Science and Technology Committee

LordsSelectest. 31 Jan 1980Email ↗● Actively Monitored
← All CommitteesWatch committee
Sessions analysed40
Commitments84
Positions144
Recommendations203

Latest Signals

14 Jul 2026UKRI should not become venture capitalUKRIPosition
“[Speaker: Professor Sir Ian Chapman] There are probably three parts in that question as well. First, I do not think that we are going to become an investor. I do not want us to get into the territory of venture capitalists. It is not our business. We should not be making equity investments. We should be enabling.”
14 Jul 2026Success means symbiosis, better management and output focusUKRIPosition
14 Jul 2026UKRI should be outcomes-led, not a grant distributorUKRIPosition
14 Jul 2026UKRI grant process is too slow for fast-moving fieldsUKRIConcern
14 Jul 2026UKRI should back interdisciplinary science and global marketsUKRIPosition
14 Jul 2026STFC cuts were not politically drivenUKRIPosition
14 Jul 2026UKRI should do more with unsuccessful applicant dataUKRIConcern
14 Jul 2026Dispute over whether STFC was disproportionately hitUKRIDisagreement

Recent Sessions

View all (40)
14 Jul 2026UKRI strategy, grants and STFC funding
3 commit5 pos3 concern2 rec1 disag
07 Jul 2026NHS innovation: genomics, AI and scaling
9 commit1 pos1 concern1 rec1 leg
30 Jun 2026MHRA, AI and personalised medicines in the NHS
12 commit2 pos3 concern3 rec
24 Jun 2026NICE, NHS innovation and AI adoption
2 commit4 pos4 concern7 rec1 leg
16 Jun 2026NHS AI, genomics and innovation scale-up
3 pos4 concern6 rec
09 Jun 2026NHS innovation, AI and clinical trials barriers
1 pos4 concern6 rec

Recent Commitments

View all (84)

Recent Recommendations

View all (203)

Frequent Witnesses

Department for Science, Innovation and Technology2× · 24 insights
Autolus Therapeutics2× · 10 insights
University of Manchester2× · 7 insights
Department of Science and Technology1× · 22 insights
Home Office1× · 21 insights
MHRA, Medicines and Healthcare products Regulatory Agency1× · 20 insights

About this committee

The Science and Technology Committee of the House of Lords scrutinises scientific and technological policy across government departments and research institutions. This select committee takes oral evidence from ministers, experts, and stakeholders and produces detailed reports on matters of scientific concern. It operates with cross-party membership to examine how science and innovation inform UK policy and practice. The committee's recent work has concentrated heavily on artificial intelligence applications in the NHS, examining how organisations including Genomics England, Health Data Research UK, and the Catapult network are deploying AI tools for health innovation and personalised medicine. It has also investigated government funding mechanisms, calling witnesses from the Department for Science, Innovation and Technology and UK Research and Innovation to understand investment priorities in AI and the future of work. A separate strand of inquiry has examined forensic science reform in policing, following evidence sessions with the Home Office on the state of forensic capabilities within law enforcement.